RESEARCHER PROFILE
Mark Pletscher
← Back to Bern University of Applied Sciences
M
Bern University of Applied Sciences
Mark Pletscher works in Health Systems, Economic Evaluations, Quality of Life, Healthcare Systems and Reforms, Healthcare Policy and Management, Hemophilia Treatment and Research, Coronary Interventions and Diagnostics. Recorded institutional associations include Novartis (Switzerland), Bern University of Applied Sciences.
65Publications
332Citations
9H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts
2018 · 53 citationsCost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
2012 · 48 citationsCost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine
2018 · 42 citationsCost-effectiveness of functional cardiac imaging in the diagnostic work-up of coronary heart disease
2016 · 34 citationsCost of acute coronary syndrome in Switzerland in 2008
2012 · 29 citationsHealth utility indexes in patients with acute coronary syndromes
2016 · 19 citationsCombined treatment with zidovudine and lymphoblast interferon-alpha in patients with HIV-related Kaposi's sarcoma
1991 · 15 citationsThe Societal Costs of Schizophrenia in Switzerland
2014 · 15 citationsThe effects of organized screening programs on the demand for mammography in Switzerland
2016 · 14 citationsDie Kosten der nichtübertragbaren Krankheiten in der Schweiz : Schlussbericht
2014 · 9 citationsSicherheit 2009: Aussen-, Sicherheits- und Verteidigungspolitische Meinungsbildung im Trend
2009 · 9 citationsCost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany
2024 · 9 citationsReal-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data
2023 · 8 citationsMarginal revenue and length of stay in inpatient psychiatry
2015 · 5 citationsSeparating the wheat from the chaff: How to measure hospital quality in routine data?
2024 · 4 citationsHealth literacy and outpatient physician visits in Switzerland
2012 · 3 citationsBurden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons
2023 · 3 citationsThree essays on supply and demand in the Swiss health care system
2015 · 2 citationsCost of acute coronary syndrome in Switzerland
2011 · 2 citationsSystematic review of cost-effectiveness modelling studies for haemophilia
2024 · 2 citationsInpatient Hospital Costs of Febrile Neutropenia (FN) as a Consequence of Chemotherapy (CHT) for Breast Cancer (BC) and Non-Hodgkin Lymphoma (NHL) in Switzerland
2013 · 1 citationsSynthesebericht : ökonomische Evaluation von Präventionsmassnahmen in der Schweiz
2010 · 1 citationsKantonale oder regionale Krankenkasse (KRK) : ökonomische Beurteilung der Vor- und Nachteile
2011 · 1 citationsInpatient hospital costs of febrile neutropenia as a consequence of chemotherapy for breast cancer and non-Hodgkin lymphoma in Switzerland
2013 · 1 citationsaldvmm: Adjusted Limited Dependent Variable Mixture Models
2021 · 1 citations
